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Abstract
We recently developed adenovirus/transposase hybrid-vectors utilizing the previously described hyperactive Sleeping
Beauty (SB) transposase HSB5 for somatic integration and we could show stabilized transgene expression in mice and a
canine model for hemophilia B. However, the safety profile of these hybrid-vectors with respect to vector dose and
genotoxicity remains to be investigated. Herein, we evaluated this hybrid-vector system in C57Bl/6 mice with escalating
vector dose settings. We found that in all mice which received the hyperactive SB transposase, transgene expression levels
were stabilized in a dose-dependent manner and that the highest vector dose was accompanied by fatalities in mice. To
analyze potential genotoxic side-effects due to somatic integration into host chromosomes, we performed a genome-wide
integration site analysis using linker-mediated PCR (LM-PCR) and linear amplification-mediated PCR (LAM-PCR). Analysis of
genomic DNA samples obtained from HSB5 treated female and male mice revealed a total of 1327 unique transposition
events. Overall the chromosomal distribution pattern was close-to-random and we observed a random integration profile
with respect to integration into gene and non-gene areas. Notably, when using the LM-PCR protocol, 27 extra-chromosomal
integration events were identified, most likely caused by transposon excision and subsequent transposition into the
delivered adenoviral vector genome. In total, this study provides a careful evaluation of the safety profile of adenovirus/
Sleeping Beauty transposase hybrid-vectors. The obtained information will be useful when designing future preclinical
studies utilizing hybrid-vectors in small and large animal models.
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Introduction
As one of the best studied and the most utilized vectors in gene
therapy, recombinant adenoviral vectors (AdVs) have the ability to
mediate high efficient transduction in a broad range of cell types
and tissues [1,2]. The advanced version of AdVs represented by
high-capacity adenoviral vectors (HC-AdVs) is characterized by
the large cloning capacity of up to 36 kb due to the deletion of all
viral coding sequences. Furthermore, HC-AdVs display a low
toxicity profile and result in long-term transgene expression in
quiescent cells. Therefore, AdVs have been applied in several
inherited and acquired human diseases such as hemophilia,
atherosclerosis, anemia, cystic fibrosis (CF) and Duchenne
muscular dystrophy (DMD) with promising therapeutic effects
[3–7].
However, as adenoviral vector genomes naturally remain
episomally and integrate into host chromosomes at low frequencies
[8–10], segregation of vector genomes to daughter cells during cell
division is inefficient compared to integrating vector systems such
as lentiviral vectors. As a result, adenoviral vectors are not
applicable in gene therapy approaches aiming at stably transduc-
ing target tissues and cells with a high proliferative potential.
To prolong the therapeutic effect after adenoviral gene transfer
in cycling cells and to stabilize the persistence of the therapeutic
DNA at a lower dose, one promising approach is to combine HC-
AdV with tools for somatic integration. A variety of adenoviral
hybrid-vectors that lead to somatic integration of the transgene
from the episomal adenoviral vector genome have been developed.
These vectors combine the highly efficient DNA delivery of
adenoviral vectors with integrating machineries for somatic
integration of the therapeutic DNA, such as transposons (retro-
transposon or Sleeping Beauty transposon) [11,12], phage
integrases (PhiC31) [13], retroviral/lentiviral integrases [14], or
adeno-associated virus (AAV) derived Rep proteins [15,16].
The SB transposase was reconstructed from a fish genome and
belongs to the TC1/mariner family of transposable elements [17].
The SB recombination process is based on a cut-and-paste
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mechanism and results in integration of the transposon into a TA-
dinucleotide of the host genome, which is the target site for the
conventionally used version of SB. The original AdV/SB hybrid-
vector system consisted of two independent HC-AdVs, of which
one HC-AdV provided the integration machinery based on the
unmodified version of the SB transposase and the other one
contained the SB transposon carrying the transgene. This
particular molecular design was called ‘‘two-vector-system’’
[12,18]. For further improvements hyperactive versions of the
SB transposase were generated including the hyperactive mutants
HSB5 and SB1006 with 10- to 100-fold increased integration
efficiencies [19,20]. Our recent study demonstrated that hyperac-
tive transposase system (HSB5) delivered by high-capacity
adenoviral vectors (HC-AdV) can result in somatic integration of
a coagulation factor IX expression cassette in murine and canine
liver, facilitating stabilized transgene expression and persistent
hematological correction [21].
However, one important safety concern for all integrating
vectors is represented by the risk of genotoxicity. Furthermore,
exploration of potential dose effects of the AdV/SB hybrid-vectors
is essential for evaluation of the pharmacokinetics and pharma-
codynamics. Herein, we characterized sites of insertion after
transposition from HC-AdVs in vivo by analysis of DNA derived
from murine liver samples using linker-mediated PCR (LM-PCR)
and linear amplification-mediated PCR (LAM-PCR). Integration
site analysis revealed a close-to- random integration pattern with
respect to integration into gene and non-gene areas and showed no
significant differences regarding to the chromosomal integration.
Furthermore, we found a correlation between the vector dose and
the efficiency of the hybrid-vector system in terms of long-term
transgene expression.
Materials and Methods
Sleeping Beauty Mediated Transposition in HeLa Cells
HeLa cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (PAA) supplemented with penicillin/strepto-
mycin (PAA), and 10% foetal bovine serum (FBS, Invitrogen). For
transposition, HeLa cells were seeded into 6-well plates one day
prior to the transfection. Cells at a confluency of 50–80%
(SuperFect Transfection, QIAGEN) or 80% (FuGENE HD
transfection, Promega) were co-transfected at a molar ratio of
3:1 with 1.4 mg of the transposon donor plasmid pTnori [22] and
various transposase encoding vectors. The latter vectors included
the HSB5 encoding plasmids pCMV-HSB5 [20], the respective
mutated and inactive SB (mSB) encoding plasmids pCMV-mSB
[22] (for details regarding the plasmids please refer to Figure
S2a). Forty-eight hrs post-transfection cells were split into 10-cm
dishes at a density of 46105 cells and 46104 cells per 10-cm dish.
After 14 days of constant selection pressure with 500 mg/ml G418,
cells were either counted for the number of G418 resistant colonies
or harvested as a transgene positive pool for recovery of integrated
transposon sequences.
Adenoviral Vector Production
All viral vectors used in this study were described in our earlier
study [21,23] and produced according to an established protocol
[24,25]. All HC-AdVs include 22 kb stuffer DNA derived from
human and mouse chromosomal DNA [3,25] to optimize
packaging of viral vectors. A detailed description of the principle
of the adenovirus/transposase hybrid-vector system can be found
in our previous publication [21]. The helper virus (HV)
AdNG163R-2 used for the HC-AdV production is an E1-
deleted first generation adenoviral vector [24]. For viral vector
characterization and titration, quantitative real-time PCR (qPCR)
with the primer pairs specific for the respective transgenes (HSB5/
mSB and cFIX) as well as E1 and L3 genes were performed. For
detailed description of each primer and titration results please refer
to Fig. 1 and Table S1. For titration of the HC-AdV-TcFIX
vector, a 150 bp PCR product was amplified. For characterization
of vectors HC-AdV-HSB5 and HC-AdV-mSB, the same primer
set was used to amplify a specific 82 bp PCR product contained in
the SB transposase gene. To detect the HC-AdV backbone we
performed a PCR detecting a region in close proximity to the right
adenoviral ITR. For evaluation of the HV contamination levels, a
primer pair and a respective probe binding to the L3-encoded
penton gene was used to amplify and detect a 67 bp PCR product.
For detection of E1 back-recombination which may cause
generation of replication competent adenovirus (RCA), primers
and probe specific to the E1 region were used for amplification
and detection of a 436 bp PCR product [26]. Genomic DNA
isolated from viral vector infected 293-cells was used as templates
for PCR reactions, except for E1-specific PCR which analyzed
genomes isolated from purified viral particles.
Animal Studies
This study was carried out in strict accordance with guidelines
and regulations of the Government of Upper Bavaria in Germany.
The protocol was approved by the Government of Upper Bavaria
in Germany according to the animal protection law (TierSchG)
(File number: 55.2-1-54-2531-92-06). All procedures were per-
formed under isoflurane anesthesia and all efforts were made to
minimize suffering. C57Bl/6 mice (6–8 weeks old) were kept and
treated according to the guidelines of the Ludwig-Maximilians-
University Munich. Animal experiments were usually ended when
stabilized transgene expression levels were observed in mice which
received the hyperactive SB transposase and when significantly
decreased transgene expression were measured in the groups
which received the inactive or no SB transposase. At the end of the
experiment animals were sacrificed. Humane euthanasia was
performed based on carbon dioxide and murine liver was removed
post mortem. As summarized in Table S2, the highest viral vector
dose was accompanied by cases of sudden death around one week
post vector administration with, until now, unknown reasons. The
condition of these mice was checked daily and the animals showed
no signs of suffering or impending death. All mice were tail vein
injected using a total volume of 200 ml. Viral vector preparations
were diluted in Dulbeccos phosphate-buffered saline (DPBS).
Rapid cell cycling of murine liver cells was induced by
intraperitoneal administration of 25 ml carbon tetrachloride
(CCl4, Sigma-Aldrich) diluted at a 1:1 ratio with mineral oil.
Blood Analysis
For the quantitative determination of alanine transaminase
(ALT) in murine serum as signal for liver toxicity, the ALT kit
(Randox) was used according to the manufacturer’s instructions.
10 ml of fresh murine serum were applied to each reaction. The
measurement was conducted in the Ultrospec 3000 spectropho-
tometer (Pharmacia Biotech).
The cFIX enzyme-linked immunosorbent assay (ELISA)
measuring cFIX levels in murine serum was performed as
described earlier [21]. In brief, for coating of ELISA plates, the
polyclonal rabbit anti-cFIX primary antibody (RACIX-IG,
Affinity Biologicals Inc.) was diluted 1:1000. After incubation
with samples obtained from treated animals the sheep horseradish
peroxidase–conjugated secondary antibody (SACIX-HRP, Affin-
ity Biologicals Inc.) was added at a dilution of 1:1000. For
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generation of a standard curve, dilutions of pooled dog plasma
with a normal range of 5 to 11.5 mg/ml cFIX antigen were used.
Generation of Sleeping Beauty Transposase-mediated
Integration Libraries Using LM-PCR and LAM-PCR
We pursued a ligation-mediated PCR (LM-PCR) approach for
isolation of transposition events. For construction of DNA libraries
high-quality genomic DNA was prepared utilizing a protocol
based on phenol-chloroform extraction. The isolation procedures
for genomic DNA were described elsewhere [13,25]. To ensure
that the isolated genomic DNA is of adequate quality, it was
checked on a 0.6% agarose gel visualizing non-fragmented
chromosomal DNA. To generate SB integration libraries, 4
blunt-end digestions with SspI, PvuII, EcoRV, or StuI were
performed by cutting 2.5 mg of high-quality genomic DNA with
80 units of the respective restriction enzyme in a total volume of
100 ml for each digestion. To ensure complete digestion, setups
were incubated at 37uC for 16 to 18 hrs.
Before setting up the ligation reaction, the digestion reaction
was purified by phenol-chloroform extraction. 100 ml phenol:
chloroform:isoamyl alcohol (25:24:1 vol/vol) were added and
transferred into phase lock gel tube (PLG heavy, 5Prime Phase
Lock GelTM) followed by centrifugation at high speed (15,000 g)
for 5 min. Then, the nucleic-acid-containing aqueous phase was
carefully transferred into a fresh tube, followed by ethanol
precipitation. The pellet was dissolved in 20 ml of Tris-EDTA
puffer (pH 7.5) for ligation. BD GenomeWalkerTM Adaptors
(Cat.No. 638901, Clontech, Heidelberg, Germany) were then
ligated to both blunt-ends of the genomic DNA fragments to
create libraries. The special amine in 39end of the short strand
insures the adaptor only ligated to blunt-end-genomic DNA
fragments and only in one direction. A nested PCR utilizing
adopter-specific primers (AP1 and AP2) and gene-specific
primers (GSP1 and GSP2) was performed. GSPs should be
derived from sequences as close to the end of the known
sequence as possible. We wanted to analyze the integration sites
after SB transposase-mediated integration and therefore, we
designed primers which bind to the transposon-specific inverted
repeat (IR) sequences. The two 27-mers primers, IR-specific
primer 1 (GSP1, 59-cct taa gac agg gaa tct tta ctc gga-39) and IR-
specific primer 2 (GSP2 59-ggc taa ggt gta tgt aaa ctt ccg act -39)
were used for the two-step PCR.
Figure 1. Characterization of the high-capacity adenoviral vectors (HC-AdVs) for in vivo applications. (a) Schematic outline of the viral
vector constructs and location of real-time PCR primers for quantitative analysis of vector genome copy numbers. HC-AdV-TcFIX represents the
transposon-donor vector for expression of canine coagulation factor IX under control of the liver specific human alpha-1-antitrypsin promoter (hAAT)
including two liver specific enhancers (HCR: hepatocyte control region; ApoE: Apo lipoprotein E). Furthermore, the vector contains a transposon
determined by inverted repeats (IRs) at the ends, which is flanked by two FRT sites for Flp-mediated excision. The HC-AdV-HSB5 contains a transgene
expression cassette for the hyperactive Sleeping Beauty (SB) transposase (HSB5) under the control of the phospho-glycerate kinase promoter (PGK)
and an expression cassette for the Flp recombinase driven by the elongation factor-1-alpha promoter (EF1a). The control vector HC-AdV-mSB
contains the inactive version of the SB (mSB). All HC-AdVs include 22 kb stuffer DNA derived from human and mouse chromosomal DNA [3,25].
Arrows inside the circles depict the real-time PCR primer binding sites specifically detecting vectors HC-AdV-TcFIX, HC-AdV-HSB5 and HC-AdV-mSB.
To detect the HC-AdV backbone we performed a PCR detecting a region in close proximity to the right adenoviral ITR (marked with dashed circles).
For evaluation of the HV contamination levels, a primer pair binding to the L3-encoded penton gene was used and to detect E1 back-recombination
which may cause generation of replication competent adenovirus (RCA), primers specific to the E1 region were used. (b) Titer and purity of the final
adenoviral vector preparations. The table summarizes the titration results and contamination levels with the helper virus used for vector production.
Shown are six representative preparations of the high-capacity vectors which were used for hepatic infusion into C57Bl/6 mice. Physical titers were
determined by OD260 nm measurements. Titration using quantitative real-time PCR was carried out to measure infectious titers and HV contamination.
The level of helper-virus contamination was defined as the percentage of transducing helper-virus particles contained in the total amount of
transducing units of the respective HC-AdV. Abbreviations: VP, viral particle; TU, transducing unit; RCA, replication competent adenovirus; n.d., not
detectable.
doi:10.1371/journal.pone.0075344.g001
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For efficient amplification of genomic DNA templates of all
sizes, the BD AdvantageTM 2 Polymerase Mix (Cat.No. 639201,
Clontech, Heidelberg, Germany) was used for PCR amplification.
For the primary PCR we used the primers GSP1 and AP1 (59-
GTAATACGACTCACTATAGGGC -39). We performed a two-
step-PCR with 7 cycles at 94uC for 25 sec, 72uC for 3 min and 32
cycles at 94uC for 25 sec, 67uC for 3 min. After the final cycle, an
extension was done with another 7 min at 67uC. Five ml of the
primary PCR products were analyzed on a 1.5% agarose gel.
Using 10-fold diluted primary PCR product as template, a
secondary PCR with primers GSP2 and AP2 (59- ACTATAGGG-
CACGCGTGGT -39) was performed based on a two-step-PCR
with 5 cycles at 94uC for 25 sec, 72uC for 3 min and 20 cycles at
94uC for 25 sec, 67uC for 3 min following with an extension for
another 7 min at 67uC. Five ml of the secondary PCR products
was analyzed on a 1.5% agarose gel. PCR products were
subcloned using the Zero BluntTM TOPOTM PCR Cloning Kit
(Invitrogen) and pre-screened by EcoRI restricted enzyme digest
flanking the multiple cloning site. Only plasmids which contained
a unique DNA segment larger than 200 bp were sequenced
utilizing the T7 and SP6 primers. For detailed description of this
method and control steps see Figures S2 and S3. For the
construction and identification of integration libraries from
in vitro transposition in HeLa cells, a previously described plasmid
rescued method was utilized [27]. The generation of Sleeping
Beauty transposase-mediated integration site libraries via LAM-
PCR in combination with an Illumina Genome Analyzer platform
was performed as described previously [28–30]. Briefly, three
enzymes NlaIII (NEB), MluCI (NEB), FspBI (Fermentas) were used
to prepare independent reactions for LAM-PCR.
Bioinformatic Analysis of Integration Sites
For LM-PCR, criteria and features of a transposition event are
shown in Figure. S3. Obtained chromosomal sequences were
blasted against the genomic sequence data base from NCBI, for
human (http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/
BlastGen.cgi?taxid = 9606) and mouse (http://www.ncbi.nlm.nih.
gov/genome/seq/BlastGen/BlastGen.cgi?taxid = 10090). For
LAM-PCR only the reads with exact adaptor sequence (23 nt)
were retained for subsequent analysis. The remaining part of the
single reads containing putative genomic sequences were cut after
50 nt. We mapped these reads to genome while only the sites with
TA nucleotides were accepted. It is of note, that for the LAM-PCR
dataset, extrachromosomal integration events referring to trans-
position events from the transposon-donor vector into the
delivered episomal adenoviral vectors HC-AdV-TcFIX and HC-
AdV-HSB5 were neglected. To map the individual integration
events in mouse chromosomal DNA, the program Bowtie was
used. To improve the data quality, we discarded all sequences for
which we obtained ,8 reads. To map these integrations identified
by LAM-PCR back to individual chromosomal DNA, the
Ensembl genome browser was used (the GRCm38.p1, Jan 2012
assembly of the mouse genome). For statistical analysis, we used
random control sets with 10,000 sites each as described previously
[28–30]. Cancer-relative-genes which were directly hit by
integration events or near (65 kb) the integration sites were
checked in a Cancer Gene Expression Databases (CGED, http://
lifesciencedb.jp/cged/) [31].
Quantification of Vector Genome Copies by Taqman
qPCR
For cFIX and SB gene copy number analysis, the same primer
pairs as for vector titration were used. A primer pair and probe
binding to the sequence near 3end ITR of FTC backbone was
used to determin the copy number of entire vector gemome. To
normalize the different samples, the same amount of genomic
DNA was analyzed by real-time PCR mouse TBP (TATA box
binding protein) was used for mouse samples and for dog samples
B2M (Beta-2-microgloblin). For detailed description of each
primer see Table S1.
Results
Dose-dependent Transgene Expression Levels and
Stability of Transgene Expression Levels during Cell
Division In Vivo
For systemic administration of high-capacity adenoviral vectors
(HC-AdVs), the gene transfer efficacy, as well as the severity of the
acute toxicity is vector dose dependent [32] and therefore, it is
important to optimize the vector dose in a pre-clinical setting. We
previously established the prototype of Sleeping Beauty (SB)
transposase-adenovirus (AdV/SB) hybrid-vector system [21]. This
vector system was based on one vector containing a transposon
encoding canine coagulation factor IX (cFIX) under the control of
a liver-specific promoter (HC-AdV-TcFIX) and a second vector
(HC-AdV-HSB5) for expression of the hyperactive SB transposase
HSB5 based integration machinery. As negative controls the third
vector encoded a mutated and inactive version of SB transposase
(HC-AdV-mSB), and the fourth vector (HC-AdV-Luc) expressed
firefly luciferase representing an unrelated control vector has been
described elsewhere [23]. Several independent viral preparations
of each HC-AdV were produced and amplified following a
standard protocol for large-scale production of HC-AdV in
spinner flasks and subsequent purification by cesium chloride
(CsCl) gradients using ultracentrifugation [24,25]. To ensure high-
quality viral vector productions, all viral vectors were character-
ized with respect to total physical titers and infectious titers
(Fig. 1b). Furthermore, low levels (,0.1%) of contamination with
helper virus (HV) were confirmed and generation of replication
competent adenovirus (RCA) during the amplification procedure
was excluded (Fig. 1b).
Herein, three different vector doses were chosen for systemic
administration into female C57Bl/6 mice. In detail, low, medium
and high total viral vector doses corresponding to 8.06109,
461010 and 261011 transducing units (TU) per kilogram body
weight (kg), respectively, were injected into the tail vein. The ratio
of co-injected vectors HC-AdV-TcFIX and HC-AdV-HSB5 used
for the integrating hybrid-vector system was 3 to 1. As negative
controls for somatic integration, mice of the control groups either
received HC-AdV-mSB encoding an inactive version of SB or the
vector HC-AdV-Luc as an unrelated control vector instead of HC-
AdV-HSB5 at medium and high vector doses (461010 or
261011 TU/kg). A summary of all vector injections in mice is
provided in Table 1. For mice which received the highest vector
dose (261011 TU/kg), high levels of transgene expression were
obtained (,10 000 ng/ml cFIX measured by ELISA) (Fig. 2a).
However, this highest dose was accompanied by cases of death
around one week post vector administration and a summary of
treated mice and the respective survival rates are provided in
Table S2. At the lowest dose, only low levels of serum cFIX were
detected (,100 ng/ml), but for the medium-dose group serum
cFIX levels of up to ,1000 ng/ml were measured over a time
period of 4 weeks (Fig. 2a).
To prove that SB-mediated integration from the episomal
adenoviral genome can facilitate the stability of transgene
expression levels in vivo, mice injected with hybrid-vectors and
controls were treated with carbon tetrachloride (CCl4). CCl4 is a
liver-toxic substance which causes death of affected hepatocytes by
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necrosis, and the amount of injected CCl4 (25 ml diluted in equal
volume of mineral oil) has been shown to result in a destruction of
about 70% of the whole liver [33]. During tissue repair rebuilding
the liver to a normal size, hepatocytes are actively dividing and
only transgenes stably integrated into chromosomal DNA are
maintained. In contrast, episomal DNA without retention signals
and origins of replication is not segregated to daughter cells during
subsequent mitoses. As a result, the non-integrated molecular
transposon forms will be lost after CCl4 treatment resulting in a
decrease of transgene expression levels.
All experimental groups were treated 3 times with CCl4
beginning 4 weeks after vector administration with one injection
every three weeks. During the time course of the experiment,
serum cFIX expression levels were monitored by ELISA one day
before CCl4 injection and at later time points once every week
(Figs. 2b, c). Mice which received the highest dose (261011 TU/
kg) of the functional hybrid-vector system cFIX expression levels
remained stable at physiological levels of cFIX (3000–5000 ng/ml)
during the whole time course of the experiment. This was in sharp
contrast to the control group which was treated with the same
vector dose but with a vector expressing inactive SB (mSB). In this
group cFIX levels showed a drop to 150 ng/ml after 13 weeks and
three rounds of CCl4 treatment (Fig. 2b). For mice injected with
the medium vector dose (461010 TU/kg) the same stability of
transgene expression was observed after CCl4 treatment as
demonstrated for the high vector dose group. Herein, stable cFIX
levels (300–800 ng/ml) were measured throughout the whole
experiment, whereas the control group receiving the same dose of
the cFIX transposon donor vector HC-AdV-TcFIX but instead of
the HSB5 encoding vector an unrelated vector (HC-AdV-Luc)
serum cFIX expression levels decreased rapidly after induction of
cell cycling. Although the cFIX levels (300–800 ng/ml) in the
medium dose group were lower than the normal range of the
physiological canine coagulation factor IX level (3000–8000 ng/
ml), they remained above the therapeutic level for treatment of
hemophilia B (Fig. 2c). However, for mice of the group which
received the lowest vector dose (86109 TU/kg), low serum cFIX
levels (,100 ng/ml) were observed within the first few weeks
dropping to undetectable levels at later time points after CCl4
administration (data not shown).
Limited toxicity studies were performed by monitoring alanine
transaminase (ALT) levels in mouse serum samples of treated mice
to detect acute toxicity associated with administration of HC-
AdVs. For all study groups, ALT levels were measured one day
before and one day post-injection. Although ALT levels were
elevated compared to the levels before injection, levels remained in
the normal range (20–80 IU/L) for all treated mice (Fig. 2d, left
panel). To conduct a long term survey of liver toxicity, two mice
from each group were monitored and 7 days post-vector injection
ALT levels decreased to similar levels as before vector injection
(Fig. 2d, right panel). To monitor indirectly hepatocytes’
damage, and to measure liver toxicity caused by CCl4 adminis-
tration, ALT levels before and after CCl4 administration were
measured in the same mice. Serum transaminase levels dramat-
ically increased to up to 600 U/l at day 1 after CCl4
administration but declined to a normal range one week later
(Fig. 2d, right panel).
Integration Site Pattern Identified from Female Mice
Treated with AdV/SB Hybrid-vectors Using LM-PCR and
LAM-PCR
In previous clinical studies utilizing retroviral vectors for gene
transfer and somatic integration genotoxicity was observed due to
activation of oncogenes [34–36]. Thus it was of great importance
to carefully investigate the risk of genotoxicity after SB-mediated
transposition from the adenoviral vector. Therefore, after stable
transgene expression was obtained in mice after systemic
administration of the AdV/SB hybrid-vector system (Figs. 2b,
c), integration sites were identified to evaluate the potential
genotoxicity of the AdV/SB hybrid-vector system. We performed
integration site analysis of genomic DNA derived from liver tissue
samples of three treated female C57Bl/6 mice which showed
Table 1. Summary of vector injections in mice.
Dose/sex Vector 1 Vector 2 Total
Weight Type TU/mouse Type TU/mouse TU/mouse TU/kg
High-dose
Female ,20 g HC-AdV-TcFIX 3.06109 HC-AdV-HSB5 1.06109 4.06109 2.061011
Male ,25 g HC-AdV-TcFIX 3.756109 HC-AdV-HSB5 1.256109 5.06109 2.061011
Female ,20 g HC-AdV-TcFIX 3.06109 HC-AdV-mSB 1.06109 4.06109 2.061011
Male ,25 g HC-AdV-TcFIX 3.756109 HC-AdV-mSB 1.256109 5.06109 2.061011
Female ,20 g HC-AdV-TcFIX 3.06109 HC-AdV-Luc 1.06109 4.06109 2.061011
Male ,25 g HC-AdV-TcFIX 3.756109 HC-AdV-Luc 1.256109 5.06109 2.061011
Medium-dose
Female ,20 g HC-AdV-TcFIX 6.06108 HC-AdV-HSB5 2.06108 8.06108 4.061010
Male ,25 g HC-AdV-TcFIX 7.56108 HC-AdV-HSB5 2.56108 1.06109 4.061010
Female ,20 g HC-AdV-TcFIX 6.06108 HC-AdV-Luc 2.06108 8.06108 4.061010
Low-dose
Female ,20 g HC-AdV-TcFIX 1.26108 HC-AdV-HSB5 0.46108 1.66108 8.06109
Summarized are vector types and doses (high-dose, medium-dose and low-dose) of adenovirus/transposase hybrid-vectors and controls used for treatment of mice
(n = 5 per group). In addition gender and body weight of treated mice are depicted. Abbreviations: HC-AdV, high-capacity adenoviral vector; TcFIX, the transposon
encoding canine coagulation factor IX; HSB5, hyperactive Sleeping Beauty transposase; mSB, inactive Sleeping Beauty transposase; Luc, luciferase expression cassette;
TU, transducing units.
doi:10.1371/journal.pone.0075344.t001
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stabilized and highest cFIX expression levels. In detail, genomic
DNA was extracted from two high-dose HSB5-mouse after 9
weeks (f1) and after 13 weeks (f2), respectively. Furthermore, a liver
sample of a mouse from the medium-dose HSB5-group 14 weeks
post injection (f3) was analyzed. As control, genomic DNA sample
from a mouse of the high-dose mSB-group 9 weeks after vector
application (f4) was investigated. An overview of all analyzed mice
for integration site analysis is provided in Table 2.
Integration site analysis was performed utilizing a ligation-
mediated PCR (LM-PCR) method (Figure S1) and a previously
published linear amplification-mediated PCR (LAM-PCR) proto-
col [30,37]. To establish the LM-PCR protocol for SB transposase
mediated transposition, we first performed experiments in HeLa
cells and evaluated the protocol at each step (Figure S2). Features
of the expected transposition events using linker-mediated PCR
(LM-PCR) are schematically shown in Figure S3a and examples
for the HSB5 and mSB groups are shown in Figure S3b. Figure
S3c shows an exemplary library derived from mouse f1 treated
with cFIX and HSB5 expressing vectors and mouse f4, which
received the inactive transposase (mSB) encoding vector. It is of
note, that the number of clones containing unique fragments is
significantly higher in mouse f1 than f4 treated with the inactive
transposase (mSB) encoding vector.
Using the LM-PCR method a total of 92 unique SB-mediated
integration sites (IS) were identified from female C57Bl/6 mice
which received the high and medium dosages of the AdV/SB
hybrid-vector system (38 IS from mouse f1; 35 IS from mouse f2;
19 IS from mouse f3). An overview of the integration site recovery
rate of the LM-PCR is provided in Table S3 and the
chromosomal distribution of chromosomal integration events is
Figure 2. In vivo application of the AdV/SB hybrid-vectors in female mice. (a) Dose-dependent effects of the AdV/SB hybrid-vectors on
transgene coagulation factor IX (cFIX) expression levels in female mice. Serum cFIX levels were measured weekly by ELISA during the first four weeks
after vector injection and before CCl4 treatment for all three vector dose settings referred to as high (n = 3), medium (n= 5) and low dose (n = 5). A
summary of vector injections and the viral load used is provided in Table 1. The normal range of cFIX (3000 to 8000 ng/ml) is indicated by a gray
shadow. Notably, 50 ng/ml is sufficient for effective coagulation (therapeutic level, dashed line). Error bars indicate the standard deviations for each
dose. (b–c) Stability of cFIX expression levels in actively dividing mouse hepatocytes. Mice were either co-injected with vectors HC-AdV-TcFIX and HC-
AdV-HSB5 (TcFIX/HSB5) or HC-AdV-TcFIX and HC-AdV-mSB (TcFIX/mSB). Persistent transgene expression levels were observed in mice which received
hyperactive transposase HSB5 (TcFIX/HSB5) in contrast to mice injected with the inactive SB (TcFIX/mSB) or an unrelated vector (TcFIX/Luc). Results
are shown for mice treated with the high vector dose (261011 TU/kg; n = 3) (b) and the medium vector dose (461010 TU/kg; n = 5) (c). The normal
range of cFIX (3000 to 8000 ng/ml) is indicated by as a gray bar. The therapeutic level (50 ng/ml) is shown as a dashed line. Arrows indicate the time
points at that animals received intraperitoneal injections of CCl4 to promote hepatic cell cycling. Error bars indicate the standard deviations for each
group. (d) Alanine transaminase (ALT) levels. ALT levels in serum samples of mice from different experimental groups were measured 1 day before
and 1 day after viral vector injection (n = 5 per group, left panel). Long-term ALT levels were measured 7days post-vector injection and before and
after CCl4 administration (right panel). The gray bar shows the normal range of ALT levels for mice (20–80 U/l). Error bars indicate the standard
deviations for each group.
doi:10.1371/journal.pone.0075344.g002
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shown in Fig. 3a. However, the limited number of recovered
integration sites after performing LM-PCR motivated us to
perform large-scale analysis of transposition events. Therefore,
we applied a previously published LAM-PCR protocol using IR-
specific primers [28–30] and obtained libraries and respective
sequences were analyzed on an Illumina Genome Analyzer
platform. Analysis of sequence reads on the mouse genome
revealed a total of 724 unique integration sites in female mice f1
and f2 after transposition from the adenoviral vector with a close
to random chromosomal integration profile (Fig. 3b).
Stability of Transgene Expression Levels and Integration
Site Profiling in Male Mice Treated with AdV/SB Hybrid-
vectors
To rule out gender differences after transposition in mice which
shown in a previous study [38], we investigated transgene
expression levels and the chromosomal distribution pattern in
male mice. Therefore, groups of male mice (n = 5) were injected
with the AdV/SB hybrid-vector system (HC-AdV-TcFIX co-
injected with HC-AdV-HSB5 at a ratio of 3:1) applying a high
dose (261011 TU/kg) or a medium dose (461010 TU/kg),
respectively. As negative control for somatic integration, mice of
the control group received HC-AdV-mSB encoding an inactive
version of SB or the HC-AdV-Luc as an unrelated control vector
at a high vector dose (261011 TU per mouse) (Table 1). Mice
treated with a medium vector dose of HC-AdV-TcFIX/HSB5
showed stable transgene expression. Although serum cFIX levels
decreased after the first CCl4 administration, they remained stable
after the second and third CCl4 administration (Fig. 4a).
However, as observed for female mice injected with high dose,
also male mice of all three groups (HC-AdV-TcFIX/HSB5, HC-
AdV-TcFIX/mSB and HC-AdV-TcFIX/Luc) died after applica-
tion of the high vector dose. An overview of survival rates of
treated mice is provided in Table S2. In concordance with ALT
levels measured in female mice, slightly elevated ALT levels were
measured 1 day post-injection for all treated male mice, while
remaining within the normal range (20–80 IU/L) (Fig. 4b).
For generation of an integration site library, two male mice (m1
and m2) from the medium vector dose group with serum cFIX
levels of 460 and 850 ng/ml were sacrificed 14 weeks post vector
infusion (see also Table 2). As in female mice, for integration site
analysis LM-PCR and LAM-PCR were performed. When
applying the LM-PCR method 44 unique transposon insertions
were identified in male mice (Fig. 4c). To obtain a larger number
of integration sites we also performed LAM-PCR using liver
samples from male mice m1 and m2 and analysis of sequence
reads on the mouse genome revealed a total of 440 unique
integration sites after transposition from the adenoviral vector
(Fig. 4d). The chromosomal distribution of all transposition
events revealed a close-to-random integration profile (Fig. 4).
Frequencies of Transposon Insertions within or Outside
of Genes and Transposition Events into Extra-
chromosomal Target Sequences
The mutagenic potential of any given integrating vector system
is one of the most essential considerations for gene therapy
applications. Normally, the integrations in genes display a higher
risk to cause genotoxicity than those which hit an intergenic
region. Thus the relation of transposon insertions to transcrip-
tional units was analyzed, aiming to determine the mutagenic
potential associated with AdV/SB hybrid-vectors. To address this
issue integration sites identified from the three female mice (f1, f2
and f3) and the two male mice (m1 and m2) were analyzed.
When using the LM-PCR method, 31 (23%) of the 136
analyzed transposition events in mouse liver were mapped within
mouse RefSeq genes (Fig. 5a). When compared to a computer-
simulated random integration profile with 26% of transposition
events into RefSeq genes [27], these data revealed a similar or
slightly reduced preference for SB-mediated integration into
mouse genes. Notably, this frequency into genes is significantly
lower when compared to murine leukemia virus (MLV, retroviral
vectors) with 50.7% and human immunodeficiency virus derived
vectors (lentiviral vectors) with 83.4% [39,40]. Among the 31
transposition events that occurred in genes, 27 were mapped
within intron sequences, and 4 were mapped in exons (Fig. 5a).
The bias towards introns may be due to the larger overall size of
introns when compared to exon sequences. Of the 105 integration
sites in intergenic sequences, 8 (7.6%) were found near genes
(65 kb), while .70% were located 50 kb upstream or down-
stream of genes (Fig. 5b). This is in contrast to AAV vectors, for
which over 38.3% of integrations were found near genes [41]. To
evaluate the risk of neoplastic changes that could potentially be
induced by the integrating vector system, those genes that were hit
by transposition events or integration sites which were localized in
close proximity of a gene (65 kb), were checked in the Cancer
Gene Expression Databases (CGED, http://lifesciencedb.jp/
cged/) [31]. Although no neoplastic change was observed
macroscopically in all treated animals, 10 transposition events
Table 2. Overview of mice used for integration sites analysis.
Vector Injection Parameters at the end of the study
Type of analysis Type of vector Dose (TU/mouse)
Time after injection
(weeks)
cFIX level
(ng/ml)
cFIX level of control group
(ng/ml)
f1 LM-PCR/LAM-PCR HC-AdV-TcFIX/HSB5 4.06109 9 4800* 750
f2 LM-PCR/LAM-PCR HC-AdV-TcFIX/HSB5 4.06109 13 3100* 150
f3 LM-PCR HC-AdV-TcFIX/HSB5 8.06108 14 520* 70
f4 LM-PCR HC-AdV-TcFIX/mSB 4.06109 9 700* NA
m1 LM-PCR/LAM-PCR HC-AdV-TcFIX/HSB5 8.06108 14 510* NC
m2 LM-PCR/LAM-PCR HC-AdV-TcFIX/HSB5 8.06108 14 780* NC
*Canine coagulation factor IX (cFIX) expression levels represent values obtained at the last measurement before extraction of liver genomic DNA.
Abbreviations: cFIX, canine coagulation factor IX; HSB5, hyperactive Sleeping Beauty transposase; mSB, inactive Sleeping Beauty transposase; TU, transducing units. f1:
female mouse 1; f2: female mouse 2; f3: female mouse 3; m1: male mouse 1; m2: male mouse 2; f4 (mSB): mSB mouse (female mouse 4); LM-PCR, linker-mediated PCR;
LAM-PCR linear amplification-mediated PCR; NA, not applicable; NC, not conducted.
doi:10.1371/journal.pone.0075344.t002
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from the AdV/SB hybrid-vectors were found to locate in or near
cancer related genes (Table S4).
In addition to the 136 transposition events in the host genome,
27 transposon integration events (with 12 unique sites) were found
to be localized within the HC-AdV genome used in this study
(Fig. 5c). This indicates that the transposon was excised from the
adenoviral vector and re-integrated into the HC-AdV genome at
various TA-dinucleotides sites. Detailed analysis of insertion sites
revealed, that they were located in the stuffer DNA contained in
the HC-AdV genome (IgkMAR and alphoid repeat DNA) [3] and
in the transgene expression cassette.
Multiple insertions were observed at two predominant sites of
the HC-AdV genome. Four integration sites were located in the
IgkMAR sequence derived from Mus musculus chromosome 6
(chr6:70675584) and 8 integration sites were found within intron 1
of the human coagulation factor IX gene derived from the Homo
sapiens chromosome X (chrX:138612987). The latter sequence
was contained in the transgene expression cassette of the vector
HC-AdV-TcFIX and located upstream of the cFIX cDNA
sequence.
After performing the LAM-PCR method, insertion frequencies
with respect to integration within or outside of RefSeq genes was
analyzed and compared to a random dataset. As shown in Fig. 5d
no significant change was observed with respect to integration into
genes, intron and intergenic regions. Only transposition from the
adenoviral vector into exons showed a slightly increased change in
Figure 3. SB-mediated integration sites from the adenoviral vector in female C57Bl/6 mice using LM-PCR and LAM-PCR approaches.
Chromosomal distribution of unique integration sites analyzed from female mice treated with functional AdV-SB hybrid vectors are compared to a
computer-simulated random integration profile. (a) Integration events identified by LM-PCR. Percentages of integration events within each individual
chromosome in comparison to the total number of identified integration sites are depicted on the upper panel. A schematic overview of
chromosomal distribution is shown on the lower panel. Respective triangles indicate the relative positions of the chromosomal transposon
integration site observed from liver genomic DNA of female mouse f1 (black triangles), female mouse f2 (grey triangles) and female mouse f3 (white
triangles). (b) Sequence reads and chromosomal distribution identified after performing LAM-PCR from female mouse f1 and f2. Percentages of
integration events within each individual chromosome in comparison to the total number of identified integration sites are depicted on the upper
panel. The lower panel shows mapping of all 724 unique integration sites identified by LAM-PCR which were mapped within the mouse genome.
Respective triangles indicate the relative positions of the chromosomal transposon integration site observed for liver genomic DNA of female mouse
1 (black triangles) and female mouse 2 (grey triangles).
doi:10.1371/journal.pone.0075344.g003
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mouse f2 and m1 (fold change of .1). Compared to the random
integration profile, there was also no significant change with
respect to the distance of integration events upstream and
downstream of genes (Fig. 5d).
Genome Status of the Hybrid-vectors in Different
Animals
The genome status and the genome copy numbers per cell of
the transduced vectors may influence the safety profile of the
AdV/SB hybrid-vector system. To further understand the
molecular mechanism associated with this adenovirus/transposase
hybrid-vector system, the genome copy numbers of each vector in
liver genomic DNA of all treated animals were determined by
quantitative real-time PCR after three CCl4 treatments. For
analysis of cFIX and SB encoding sequence, the same primer pairs
as for vector titration were used (Fig. 1). To quantify the total
amount of adenoviral vector genomes we also used a primer pair
specifically detecting the HC-AdV backbone. To normalize the
Figure 4. SB-mediated integration sites in male C57Bl/6 mice. (a) Stable cFIX expression in male mice after treatment with AdV/SB hybrid-
vectors. Male C57Bl/6 mice (n = 5) were co-injected with HC-AdV-TcFIX and HC-AdV-HSB5 at a ratio of 3 to1 using a medium total vector dose (461010
transducing units (TU) per kilogram body weight [kg]). A detailed summary of vector injections and the viral load used is provided in Table 1. ELISA
measurements for detection of canine factor IX in mouse serum were performed periodically and carbon tetrachloride (CCl4) injections are indicated
as arrows. The normal range of cFIX (3000 to 8000 ng/ml) is indicated by gray bar. Notably, 50 ng/ml is sufficient for effective coagulation
(therapeutic level). Error bars indicate the standard deviations for each group. (b) Alanine transaminase (ALT) levels. ALT levels in serum samples of
male mice treated with functional AdV/SB hybrid-vectors (HC-AdV-TcFIX/HSB5; high dose: 261011 TU/kg; medium dose: 461010 TU/kg) as well as
with non-functional variants (HC-AdV-TcFIX/mSB: high dose: 261011 TU/kg; HC-AdV-TcFIX/Luc: high dose: 261011 TU/kg) are shown. Samples from 1
day before and 1 day after vector injection were analyzed for all groups (n = 5 per group). The grey shadow shows the normal ALT range for mice (20–
80 U/l). Error bars indicate the standard deviations for each group. (c) Chromosomal distribution of SB-mediated integration events in male C57Bl/6
mice using LM-PCR. Integration sites analyzed from genomic DNA derived from liver samples of two male mice (m1 and m2) treated with the AdV/SB
hybrid vectors were compared to a computer-simulated random integration profile [23]. Percentages for integration events within each individual
chromosome in comparison to the total number of identified integration sites are summarized (upper panel). The lower panel shows the overall
distribution of transposition events in murine host chromosomes. Male mouse m1 (black triangles) and male mouse m2 (grey triangles) are shown.
(d) Integration events identified from male mice after performing LAM-PCR. The relative position of all unique integration sites identified from male
mice m1 and m2 after SB-mediated transposition from the adenoviral vector (AdV/SB hybrid-vector system) were identified by LAM-PCR. The top
panel analyzes percentages of integration events within each individual chromosome in correlation to the total number of identified integration sites.
The mapped integration sites are shown in the bottom panel. Respective triangles indicate the relative positions of the chromosomal transposon
integration site observed for liver genomic DNA of male mouse m1 (black triangle) and male mouse m2 (grey triangles).
doi:10.1371/journal.pone.0075344.g004
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different samples, the same amount of genomic DNA was
analyzed by real-time PCR using mouse TBP (TATA box binding
protein) for mouse samples and for dog samples B2M (Beta-2-
microgloblin).
In all treated animals which received HSB5, the cFIX gene
copy numbers per cell were at least one log higher than vector
genome copy numbers measured for the HSB5 transposase gene
(Fig. 6a). However, this was different for mice which received the
HC-AdV encoding mSB (Fig. 6a). Furthermore, for the PCR
detecting the FTC backbone, copy numbers per cell were
significantly lower compared to the cFIX copy numbers for mice
which received the hyperactive HSB5 (Fig. 6a).
Next we analyzed mice which were used for integration site
analysis (female mice f1–f3, male mice m1 and m2, mSB viral
vector treated female mouse f4). Based on our previous study [21]
and for direct comparison, we also analyzed one sample of a dog
(dog 1) which was treated by the SB transposase hybrid-vector
system showing long-term expression of cFIX for several years
post-injection. In contrast to the results obtained from a semi-
quantification PCR in our historical study [21], the SB transposase
gene was detectable by real-time PCR in all animals ranging from
Figure 5. Frequencies of insertions rescued from murine liver within or outside of genes and extrachromosomal target sites after
performing. (a) Percentage of integration sites which were identified to be intragenic, intergenic, in intron, or in exons after performing LM-PCR. f1:
female mouse 1; f2: female mouse 2; f3: female mouse 3; m1: male mouse 1; m2: male mouse 2; total: all integration sites from these five mice;
random: computer predicted data [53]. (b) LM-PCR derived integration sites and their proximity to genes. The number above the horizontal arrows
indicates the number of integration events with varying proximities to genes. The X-axis describes the distance of each integration site upstream and
downstream of the nearest gene in kilobases (kb). The Y-axis shows the percentage of integration events. (c) Transposition into extrachromosomal
target sequences using the LM-PCR method. The upper panel schematically shows the vector constructs of the transposon encoding vector HC-AdV-
HSB5/mSB and the transposon-donor vector HC-AdV-TcFIX. The lower panel shows a detailed map of the stuffer DNA and the transgene. The stuffer
DNA consists of two parts: IgkMAR (the matrix attachment region of the murine immunoglobulin k locus) and alphoid repeat DNA (alphoid repeat
DNA sequences from human chromosome 17). The core transgene was represented by the canine coagulation factor IX cDNA (cFIX) including a
portion of the first intron of the human FIX gene expressed under the control of the liver-specific alpha-1-antitrypsin promoter (hAAT). The triangles
show the relative positions of the extrachromomal integrations sites which were mapped to the injected adenoviral vector genomes. IR, transposon
derived inverted repeat; ITR, adenovirus derived inverted terminal repeat; PGK, phosphor-glycerate kinase promoter, FRT, FLP recombinase
recognition sites; EF1a, elongation factor-1-alpha promoter; HSB5, hyperactive Sleeping Beauty transposase HSB5. (d) Characterization of adenovirus/
transposase hybrid-vectors mediated integrations identified by LAM-PCR method. Insertion frequencies relative to a random dataset are shown with
respect to integration within and outside RefSeq genes (left panel), and distance upstream and downstream of genes (right panel). The bars depict
fold changes of integration frequencies relative to the random distribution profile.
doi:10.1371/journal.pone.0075344.g005
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0.004 to 0.106 copies per cell. However, in all AdV/SB
transposase hybrid-vectors treated animals except for the mouse
f4 which received the inactive version of transposase (mSB), there
was at average an 8-fold increase of cFIX gene copy numbers
compared to the genome copy numbers measured for the SB
transposase gene. It is of note that the two female mice f1 and f2,
which received a high dose vector infusion (261011 TU/kg),
highest genome copy numbers (0.811 and 0.581 copies/cell for the
transposon-encoding sequence and 0.106 and 0.080 copies/cell for
transposase-encoding sequence) and highest cFIX expression levels
(4500 and 3100 ng/ml at the last time point measured) could be
measured (Fig. 6b). Therefore, we could maintain almost one
copy per cell of the transposon encoded transgene. In contrast,
mice which received a medium vector dose (f3, m1 and m2,
461010 TU/kg) the genome copy numbers and transgene
expression levels were lower (Fig. 6b) indicating that there is a
correlation between vector dose and transgene expression.
Notably, for all treated animals SB transposase sequences were
still detectable, demonstrating that HC-AdV genomes encoding
the transposase were still present in transduced liver. However, it
remains to be analyzed whether SB transposase is still actively
transcribed or whether the transgene expression cassette was
silenced by epigenetic effects.
Discussion
Herein, we analyzed efficacy and safety issues of our recently
developed adenovirus-transposase hybrid-vector utilizing the
hyperactive Sleeping Beauty transposase HSB5. This vector
system was shown to result in stabilized transgene expression in
mice even during rapid cell cycling and it was demonstrated that
this hybrid-vector can mediate long-term phenotypic correction in
a hemophilia B dog [21]. Herein, we carried out dose escalation
studies and we evaluated genotoxicity which can potentially be
caused by somatic integration of the transposon after transposition.
We showed that the adenovirus-transposase hybrid-vector could
mediate persistent transgene expression (Fig. 2), however, a
vector dose as high as 261011 TU/kg led to lethal toxicity 5 to 14
day post-injection in a significant number of mice receiving
various vector settings (Table S2). It is of note that healthy
C57Bl/6 mice at 6–8 weeks of age were used for this study and
that 1 day post-infusion ALT levels were increased while
remaining in a normal range for all treated mice up to one week
Figure 6. Vector genome copy numbers in liver after in vivo application. Liver genomic DNA was analyzed by quantitative real-time PCR
using primers and probe detecting the HC-AdV vector backbone and primers detecting the cDNAs of the two main functional genes cFIX and SB. As
internal control TBP for mouse and B2M for dog were used. (a) Analysis of the vector genome copy numbers in murine liver of female and male mice
(n = 3 per group), with respect to sex, vector dose used and transposase type. (b) Vector genome copy numbers and serum cFIX levels of individual
mice which were used for integration site analysis. Four female mice (f1–f4) and 2 male mice (m1, m2) were analyzed. As a comparison we also
analyzed a sample derived from dog liver after hybrid-vector infusion [21]. Dog indicates dog D1 which received 9.461011 vps/kg (equals to
4.761010 TU/kg) [21]. Error bars indicate the standard deviations for each group.
doi:10.1371/journal.pone.0075344.g006
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post-injection (20–80 U/l) (Fig. 2d). We observed fatalities in
mice independent of the transgene encoded by the adenoviral
vector in the high vector dose setting (261011 TUs/kg body
weight, equals approximately 4.061012 VPs/kg body weight)
(Table S2). Therefore, we hypothesize that expression of SB
transposase and/or FLPe recombinase may not be the reason for
the high mortality rate. Also supraphysiological cFIX expression
levels can most likely be excluded as a reason for the high
mortality rate, because to our knowledge there is no evidence in
the literature that this may cause unwanted side effects in mice.
However, adapted immune responses against the incoming human
adenovirus capsid may have contributed at least in part to the
observed toxicity. It is of notion that numerous previous studies
showed that systemic administration of HC-AdVs led to dose-
dependent acute toxicity. However, those toxicities were observed
shortly after vector injection (,48 hrs) associated with activation
of the innate inflammatory immune response [32,42,43]. Also, in
one clinical trial using intravascular administration of HC-AdV at
a dose of 4.361011 VPs/kg into a hemophilia A patient, transient
inflammatory response with hematologic and liver abnormalities
was observed [44]. It is of note, that the dose chosen in our study,
even the high dose (261011 TU/kg, equals approximately
4.061012 VPs/kg) was tolerated in other studies. For instance,
although associated with acute toxicity, 5.661012 VPs/kg of the
gutless adenovirus HC-AdV-LacZ was a safe dose in baboons, and
7.5 6 1012 VPs/kg of the apoE expressing HC-AdV or
361011 particles per mouse of a VLDLR expressing HC-AdV
were safe doses in mice [5,45,46]. Nevertheless, it can be
concluded from this study that a dose of $261011 TU/kg of the
HC-AdV/SB hybrid-vectors is above the maximum tolerable dose
in mice and that a dose #86109 TU/kg is not sufficient for
achieving stabilized and long-term transgene expression. There-
fore, there seems to be a relatively narrow therapeutic window for
the hybrid-vector system analyzed in the present study.
After performing LM-PCR and LAM-PCR to characterize
transposition events, we identified 163 and 1164 integration site,
respectively. We found that transposase-mediated integration
events from the adenoviral vector genome displayed a nearly
random integration profile with respect to integration into gene
and non-gene regions (Fig. 5a, d). This finding was in
concordance with results described in other studies using either
a lentiviral-transposase hybrid-vector system [28–30] or a non-
viral approach based on plasmids [27].
Interestingly, female mice (f1, f2 and f3) and male mice (m1 and
m2) revealed a bias towards integration in the X-chromosome
when using the LM-PCR method (47% for female mouse f1, 37%
for female mouse f2, 13% for male mouse m1, 9.5% for male
mouse m2) (Fig. 3a and 4c), but the LAM-PCR showed no
significantly increased bias towards the X-chromosome (Figs. 3b
and 4d). This result indicated that chromosomal distribution is
influenced by the method used and the total number of identified
integration sites. For instance, the LM-PCR method applied in the
present study is strongly dependent on the restriction enzyme used
for digestion of isolated genomic DNA, which may influence the
distribution of recovered integration sites from host chromosomes.
However, comparing the two methods for analysis of transposition
events, one important advantage of the LM-PCR method is the
fact, that this method can be used by any laboratory and not only
by specialized groups. LAM-PCR on the other hand allows
identifying a larger number of transposition events. It is of note,
that our LM-PCR-based method was also used in a system
utilizing PhiC31 integrase for somatic integration from the
adenoviral vector [37] without finding a preference for the X-
chromosome. In general it also needs to be considered that
administration of CCl4 may influence the vector fate and the
integration pattern. We believe, however, that transposition occurs
within the first few days after vector injection and CCl4 injection
was started several weeks after vector injection. Another issue
which needs to be considered is the likelyhood that the remaining
episomal adenoviral vectors may be inserted into the host genome
when rapid cell cycling is induced by the liver toxin.
We identified 1164 transposition events in female and male
mice referring to the mouse genome when applying the LAM-
PCR method and it needs to be emphasized that the Illumina
genome analyzer technology should have the potential to analyze
even more integration sites. However, it is of note, that extra-
chromosomal integration events into the delivered adenoviral
vector referring to transposition events from the transposon-donor
vector into the delivered episomal adenoviral vectors HC-AdV-
TcFIX or HC-AdV-HSB5 were neglected when analyzing the
LAM-PCR dataset. Since 27 of 163 transposition events (17%)
were identified to be located in the delivered adenoviral vectors
when using LM-PCR (Fig. 5c), even more extrachromosomal
transposition events can be expected for the LAM-PCR approach.
Extra-chromosomal target sites for SB transposase were also
described in a plasmid-based study [27], in which the promoter
region and the polyadenylation signal region were found to be a
‘‘hot spot’’ including 85% of all extra-chromosomal transposition
events. The present study, however, showed no bias towards
promoter or polyadenylation signal regions (Fig. 5c).
Copy number analysis showed detectable adenoviral vector
genomes in all mouse groups (ranging from 1021 to 1023 copies
per cell) (Fig. 6a), however, since the frequency of recombinant
adenoviral vector genome integration is known to be rather low
[8–10], we assume that most of these viral vector genomes
remained episomal. Moreover, in the mouse groups which
received the hyperactive transposase HSB5, the cFIX copy
numbers detected were almost one log higher than that of the
FTC backbone (Fig. 6a), indicating that the persistent cFIX
expression is mainly associated with SB-mediated integration of
the transgene and not the adenoviral genome persistence. Another
concern from this study is that genomes of transposase encoding
vector (HC-AdV-HSB5/mSB) were still detected in the hybrid-
vectors administrated mice and the sample derived from one
treated dog which is probability due to the persistence of the
adenoviral vector genome (Fig. 6). It needs to be pointed out that
duration of transposase expression was not analyzed in our study
and that long-term exposure of liver cells to the transposase gene
product may cause liver toxicity which may have a direct impact
on cell growth. For instance, long-term high level SB transposase
expression may cause secondary transposition, potentially resulting
in an increased risk for neoplastic changes. However, the
frequency of SB remobilization from mammalian cell chromo-
somes was described to be low (1024 to 1026 events per transfected
cell) [47–49]. Another concern could be a direct impact of SB
transposase expression on cell growth. For instance, Galla and
colleagues observed a dose-dependent G2/M cell cycle arrest and
induction of apoptosis caused by the over-expressed SB transpos-
ase [50]. Notably, in this study cytotoxicity was also observed in
the absence of a co-delivered transposable element. In our study
we used the PGK promoter to control expression of SB
transposase (Fig. 1a). This PGK promoter is relatively weak
and therefore, over-expression of SB transposase can be ruled out
at the time. To actually address this question, further studies need
to be performed analyzing transcription and expression levels of
SB. Interestingly, a recent study examined SB transposase gene
copy numbers after delivery of the SB system into primary human
T cells. They also detected a relatively high copy number of SB
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transposase but neither the transposase mRNA nor protein was
detectable [51]. Nevertheless, due to the high copy number of
detectable transposase found in this and several other studies, SB
transposase delivery needs to be carried out with caution. To avoid
long-term expression of SB transposase, dose-controlled mRNA
delivery or delivery of an expression cassette for which the
transposase gene is expressed under the control of an inducible
promoter could be performed [50–52].
In summary, our results demonstrated that the AdV/SB hybrid-
vector system can facilitate long-term stable transgene expression
in a vector dose-dependent manner, but the vector dose need to be
strictly limited to non-toxic level (must be below 261011 TU/kg).
Importantly, this report describes for the first time a genome-wide
analysis of transposition events after application of the AdV/SB
hybrid-vector system in vivo. The relatively lower percentage of
transposition events identified in genes is encouraging with respect
to genotoxicity.
Supporting Information
Figure S1 Schematic outline of a ligation-mediated PCR
(LM-PCR) method to determine integration sites. (a)
Genomic DNA digest: highly purified genomic DNA was digested
with four blunt-ended restriction enzyme nucleases: SspI, PvuII,
StuI, EcoRV. (b) Linker ligation: linker from the BD Genome-
WalkerTM kit was ligated to the blunt ends of the genomic DNA
fragments creating four libraries. (c) Two-step PCR: the first PCR
was performed with a gene-specific primer (GSP1) binding to the
transposon flanked sequence IR, and an adaptor specific primer
(ASP1) which specifically recognized the 59 end of the adaptor-
ligated genomic fragments. The second PCR was a nested PCR
performed with primers binding to sequences located within the
first PCR product (GSP2 and ASP2). (d) Subcloning and
sequencing of PCR products containing the chromosomal DNA
flanking the integrated transposon: PCR products generated by
the nested PCR were subcloned into the pCR-blunt II-TOPO
vector (3.5 kb). After screening of clones by EcoRI digestion, the
genomic DNA-transposon interface sequence was sequenced for
each clone and chromosomal location of the genomic DNA
identified.
(TIF)
Figure S2 Establishment of the ligation-mediated PCR
(LM-PCR) method to determine integration sites based
on the GenomeWalker Kit (BD). (a) Methodical set-up for
evaluation of SB-mediated transposition from plasmids in cultured
mammalian cells. Hela cells were co-transfected with the donor
plasmid pTnori containing an expression cassette for neomycin
and the plasmid pCMV-HSB5 encoding the hyperactive Sleeping
Beauty transposase HSB5 or pCMV-mSB containing a non-
functional version of the transposase. After transfection, cells were
cultured for 14 days under selection with G418 for neomycin
resistant cells. DNA isolated from grown cell colony pools were
used for establishment of the LM-PCR method for analysis of
integration sites. IR, transposon inverted repeats; SV40, simian
virus promoter; neo, neomycin-phosphotransferase gene; Tn5:
bacterial promoter; ori: bacterial ori; CMV, cytomegalovirus
promoter; HSB5: hyperactive Sleeping Beauty transposase HSB5;
mSB: mutated, non-functional Sleeping Beauty transposase. (b)
Quality of genomic DNA extracted from transduced cells. The size
of genomic DNA was analyzed by loading 100 ng of genomic
DNA on a 0.6% agarose/EtBr gel. For optimal processing,
genomic DNA should be bigger than 50 kb and no or minimal
smearing should be visible indicating low degree of degradation.
M, peqGOLD 1 kb DNA-Ladder (peqlab); Lanes 1–3, genomic
DNA isolated from three independent dishes with pools of Hela
cells containing somatically integrated transgenic DNA. (c)
Control for sufficient digestion of genomic DNA with restriction
enzymes SspI, PvuII, StuI, EcoRV. The degree of digestion of the
genomic DNA for generation of respective libraries was controlled
by loading 100 ng on a 0.6% agarose/EtBr gel, a smooth smear in
each lane shows that the genomic DNA can be completely
digested by the restriction enzymes. (d) Evaluation of the primary
PCR product: 20 ml and 5 ml of the primary PCR products (total
volume: 50 ml) were separated on a 1.5% agarose/EtBr gel. For a
successful PCR, a multiple banding or a smearing pattern could be
observed with product sizes ranging from 500 bp to 5 kb except
for the negative control (H2O). Depicted arrows indicate bands
visualizing distinct PCR products. (e) Evaluation of secondary
PCR products (nested PCR): 5 ml of the secondary PCR products
were analyzed on a 1.5% agarose/EtBr gel and respective
products should be present as prominent bands within the range
from 200 bp to 6 kb. (f) Visualization of clones of the integration
site library. Size differences of plasmids containing the subcloned
PCR products within the pCR-blunt II-TOPO vector indicate
different integration events. (g) Screening of integration site library
for unique integration events by restriction enzyme digest. A
EcoRI restriction digest is performed to excise subcloned DNA
fragments. This allows identification of bands with an unique size
visualized on an agarose gel (valid PCR products should be bigger
than 0.2 kb to enable sequencing and subsequent identification).
(TIF)
Figure S3 Features of the analyzed transposition events
using linker-mediated PCR (LM-PCR). (a) Criteria and
analysis of DNA sequences and transposition events determined by
the LM-PCR method. Within the plasmids generated by
subcloning of PCR-amplified genomic fragments, the genomic
DNA sequences are flanked by the vector sequence and the IR at
one side and the linker sequence and the vector sequence on the
other side. The IR sequence consists of 34 base pairs containing
the sequence of the nested primer GSP2 and the rest of the
flanking part of the IR. The sequence next to the end of the IR
end regularly begins with a TA-dinucleotide sequence and
resembles the genomic location of the integration site. The linker
consisting of 36 bps contains the sequence of the linker restricted
by the nested primer ASP2. Furthermore, the genomic sequence
and the linker is separated by the part of the restriction enzyme
(RE) site remaining from the digestion step during the generation
of the genomic library. SP6/T7: sequencing primers used for
identification of inserts incorporated into the pCR-blunt II-TOPO
vector; IR: inverted repeat; TA: dinucleotide sequence (genomic
target site for the SB transposase). (b) Analysis of sequenced
Sleeping Beauty mediated transposition sites within the genome of
Hela cells. For verification of a SB-mediated integration site, the
sequence of the nested primer (underlined), the sequence at the
end of the inverted-repeat (IR; depicted in italic letters) and the
TA dinucleotide target site (central shaded box) have to be within
the determined sequence. * non-specific PCR product; # random
integration event; 1 background (sequence derived from the
donor-vector containing the transposon). (c) Screening of integra-
tion sites based on restriction enzyme analysis after PCR
amplification of integration sites utilizing the linker-based method
and subsequent subcloning in the TOPO cloning vector. EcoRI
restriction enzyme digests of subcloned PCR products derived
from HSB5 mouse f1 (left side) and mSB mouse f4 (right side) are
shown. For subsequent sequencing of PCR products subcloned
fragments smaller than 0.2 kb were excluded.
(TIF)
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Table S1 Oligonucleotides used in this study.
(DOC)
Table S2 Fate of all HC-AdV injected mice (summary of
survival rate).
(DOC)
Table S3 Summary of the recovery rate of integration
events based on the ligation-mediated PCR (LM-PCR)
method.
(DOC)
Table S4 Transposon insertions in or near cancer
related genes using LM-PCR.
(DOC)
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